- Home
- /
- Cagrilintide 10mg
Cagrilintide 10mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that plays a role in appetite regulation, gastric emptying, and post-meal glucagon suppression.
Cagrilintide is currently in advanced clinical trials as both a standalone compound and in combination with Semaglutide (the CagriSema programme). Early clinical data from the combination approach has shown results exceeding either compound alone, representing a novel dual-hormone strategy in metabolic research.
This compound operates through an entirely different mechanism than GLP-1 or GIP agonists, making it a valuable addition to metabolic research protocols examining appetite regulation through the amylin pathway.
Independently Verified Purity: 99.625%
Tested by Janoshik Analytical (Prague) — Task #88845, 19 November 2025.
Actual content: 10.56mg per vial (5.6% overfilled vs stated 10mg dose).
Batch: 2025J52-11 | Green cap identifier.
Verification: janoshik.com/verify — Key:
BXQDTDVRH3SW
Specifications
| Also Known As | NN9838 |
| Developer | Novo Nordisk |
| Receptor | Amylin receptor agonist (AMY1, AMY3) |
| Molecular Weight | ~3900 g/mol |
| CAS | 2375949-99-8 |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-CAGRILINTIDE10MG |
| Compound Name | Cagrilintide 10mg |